Oxford Biomedica plc – Market Performance (20 October 2026)
Trading Activity
Share price increased by 0.39 % during the 24‑hour period ending at 06:00 PM Central Europe on Tuesday 20 October.
Current trading price: GBX 521.
Shares available for trading: 1.2 million.
Market capitalization: GBX 821.2 million.
Trading volume in the last 24 hours: GBX 178.6 million.
Year‑to‑date change: +9.89 % since the end of the previous month.
Technical Indicators
200‑day simple moving average: GBX 616.33.
52‑week high: GBX 962 (recorded 16 January 2026).
52‑week low: GBX 420 (recorded 4 September 2026).
Recent Market Commentary
The share price movement was noted in broader market commentary, which highlighted a decline across the FTSE 100 as traders processed recent Chinese economic data and awaited key U.S. technology earnings.
No company‑specific announcements or earnings reports were released during this period.
Comparative Performance of Related Stocks (Last 24 Hours)
| Stock | Ticker | Price Change | Current Price (GBX) | Market Cap (GBX mn) | PE Ratio |
|---|---|---|---|---|---|
| Applied Nutrition | APN.L | –0.34 % | 289.5 | 971.8 | – |
| Telecom Plus | TEP.L | –0.11 % | 893 | 916.5 | 8.85 |
| Aep Plantations | AEP.L | –4.22 % | 174 | 882.5 | 9.88 |
| Avon | AVON.L | –0.4 % | 2,400 | 972.1 | 55.23 |
| Polar Capital | POLR.L | –0.27 % | 755 | 934.6 | 12.64 |
- Telecom Plus announced completion of a series of share repurchase transactions during the first week of October 2026, holding the repurchased shares in treasury.
- Aep Plantations continued its share‑buyback programme in October, adding 26,800 shares on 19 October and 26,500 shares on 16 October to its treasury.
- Polar Capital reported a purchase of over 100,000 ordinary shares by its Employee Benefit Trust between 12 and 16 October 2026 to meet future vesting obligations.
Company Overview
Oxford Biomedica plc is a biotechnology company headquartered in Oxford, United Kingdom. The company develops gene and cell therapy treatments for serious diseases, primarily using its FDA‑approved lentiviral vector delivery platform for both in‑vivo and ex‑vivo applications. Oxford Biomedica collaborates with global pharmaceutical and biotech partners while building its own portfolio of product candidates. The company is listed on the London Stock Exchange. For further information, visit www.oxfordbiomedica.co.uk .
